Bio Job Blog : Bio Jobs : Biotechnology Jobs : Biopharmaceutical Jobs : Bioscience, Biotech Jobs : Bio Job Blog : Biocareer : Bio-Business Training, Biotechnology Training : Jobs in Biology : Internships in Biology : Internships in Biotechnology

As somebody who has been unemployed more than once, unemployment can be depressing, very frustrating and extremely worrisome.  In addition to sending out resumes and networking, I highly recommend using the free time that you have at your disposal to learn new skills to either make your life more manageable or to increase your employability.  Obviously, unemployed persons usually don’t have the money to enroll in formal training programs but thanks to the Internet and social media there are a variety of free tools and options out there for people looking to pick up new skill sets. 

Amber Johnson at OnlineDegreePrograms.org has put together a list of 100 skills you should learn (for free) while unemployed. While many of her suggestions are intuitive, there are a few on the list that may surprise you and quite possibly improve your chances of finding a new job!

100 Skills You Should Learn (for Free) While You’re Unemployed

People Skills and Networking

Become a better networker, small talker and listener to improve your job prospects.

1. Listen: Become a better listener by tuning out background noise and making eye contact.
2. Build a portfolio: Have an organized hard copy and file on your computer that succinctly and accurately represents your best work.
3. Share the conversation: Don’t dominate the conversation: learn to take a step back when you’ve said your part, and know when to jump in if the conversation becomes all about them.
4. Understand your emotional intelligence: Become more socially aware and learn to evaluate your own emotions and reactions.
5. Bring personality to a company: Being able to provide something that people can relate to behind the big corporate name is priceless.
6. Make your resume Internet ready: Make sure your updated resume will display nicely when you e-mail it and post it on job sites.
7. Set an example: Learn how to inspire others by doing what you love, being expressive, and helping others along the way.
8. Expand your network: Tap into contacts two or three degrees removed from your regular network.
9. Network or interview on the phone: Stop working on your in-person networking skills for a minute and remind yourself how to win someone over via the telephone.
10. Give a strong handshake: Impress people with your confidence by giving a better handshake.
11. Remember people’s names: From face association to repetition, there are various ways to remember a person’s name.
12. Know when and how to use icebreakers: Become the one other people depend on to make connections and feel comfortable.
13. Make a point to grow existing relationships: Don’t just get to know people on the surface: get to know business and personal contacts on a deeper level.

Life hacks

From making your own coffee to saving gas, here you’ll learn valuable skills that save you money, too.

14. Make your own coffee: Cut back on expensive coffee runs by learning how to make your own cup.
15. Comparison shop: Comparison shopping will save you money and turn you into a more responsible consumer and better product researcher.
16. Learn how to be more energy efficient: Save money on energy bills at home and at your new office when you get hired again.
17. Save gas: Minimize the number of times you have to spend money on gas by making each fill up last longer.
18. Eat cheaply: Watch this video to learn how to make yummy meals out of dollar-store food.
19. Discover your life purpose: Discover how to tap into your life purpose and passion to give you more direction in your job search and life goals.
20. Face reality: Accepting and dealing with reality will help your career and your personal life.
21. Cook: While you have the time, learn to cook healthy, budget-friendly meals for yourself, and use leftovers.
22. Being positive: Stop complaining and turn yourself into a positive thinker.
23. Meditate: Meditation will help get you through the tough times.

Productivity and Task Mastering

Stay productive and learn to stay on task, avoid procrastinating and set goals even when you’re unemployed.

24. Get up on time: Learn how to get up right when your alarm goes off to get a fresh, productive start to the day.
25. Funneling: The art of funneling means that you know how to manage incoming projects and to-do lists, and prioritize them accordingly.
26. Speed reading: You’ll be able to stay on top of industry reports, news stories, job postings and more when you learn to speed read.
27. Break things down: Turn difficult tasks into easier ones by breaking them down and taking it day by day.
28. How to set goals: Setting goals will help you be more successful, in the short-and long-term.
29. Overcome fear of failure: Fear of failure wastes time and prevents you from doing what you really want.
30. Beat procrastination: This step-by-step guide will help you beat procrastination.
31. Prepare a to-do list: A well-organized to-do list will keep you on track and save time.
32. Learn the Pomodoro Technique: Those who are anxious about meeting deadlines should master this technique.
33. Eliminate distractions: Learn how to tune out distractions and interruptions.

Computer and Internet Skills

These skills will turn you into a better Googler, blogger and typer.

34. Online research: Besides helping you find a job, solid Internet research skills will make you a desirable job candidate.
35. Learn how to use different operating systems: Train yourself to learn how to use Macs, Windows and Linux systems.
36. Hack Google: Learn all of the Google shortcuts and business tools.
37. Build a high-traffic website: Promote yourself and show potential employers how you can improve their websites.
38. Use Facebook productively: Turn Facebook into a business tool for networking, branding and more.
39. Basic web design: Employers will snatch you up if you know even basic web design.
40. Blog: Becoming an expert blogger takes time, so use your unemployment to learn the technical and business side of blogging.
41. Telecommute: Learn how to work with others online.
42. Learn to type: Typing quickly and correctly saves you time and makes your work look more professional.
43. Create a podcast: This fun and simple skill could increase your job prospects too.

Organization

Organize your personal and professional life by learning these skills.

44. Be punctual: Being punctual forces you to map out your day according to appointments and to-dos.
45. Use spreadsheets: Spreadsheets are great organizing tools and are used at almost every office.
46. Sort email: Set up folders, archives, filters and searches to organize all of your emails.
47. Prioritize: Prioritize your tasks so that it’s easier to work down your to-do list.
48. Use a calendar: Make use of an online calendar to set up alerts and more tools to help you stay organized.
49. Improve your memory: Practice different techniques to improve your memory.
50. Organize your closet: A better organized closet will help you stay on top of chores and get ready faster in the mornings.

Writing

Write better emails, use better grammar and influence others with your writing.

51. Write better emails: Write effective, impressive emails and subject headings.
52. Learn correct grammar: Poor grammar will hurt your career prospects in a heartbeat.
53. Persuasive writing: Learn how to write more persuasively and passionately.
54. Write for the Internet: Writing online pieces is completely different than writing for traditional media.
55. Write the perfect cover letter: Write a better opening and remember to include all the important details.

Confidence

These skills will boost your confidence and make others take notice of you.

56. Work on body language: Learn how to stand confidently, make eye contact and relax.
57. Trust yourself: If you’re constantly worried about what other people think of you and your decisions, you’ll come across as weak and inexperienced.
58. Examine your soft skills: Discover what soft skills make you a good employee: leadership, dedication, or the ability to motivate others.
59. Master the job interview: Be prepared, be confident and research the company and person you’re interviewing with.
60. Handle rejection: Stay confident and inspired even when you aren’t getting call backs.

Promotion and Branding

The skills you learn to promote yourself now will pay off later.

61. Design for branding: Learn how to think creatively and visually in order to promote your brand.
62. Understand copyright: Learn about copyright laws and how to get your own patent.
63. Promote yourself without bragging: You’ve got to learn how to relate to people and make them interested in you and your experience, without bragging.
64. Know — and own — your best attributes: Show off your ability to close a sale or put on your resume that you’re the one to call if a decision needs to be made.
65. Being accountable: Monitor what’s being said about you online and on social networks, keep track of your brand’s reputation, and own up to any mistakes or issues people have with you.
66. Use Twitter effectively: Learn how to use Twitter to boost your brand and reputation, not diminish it.
67. Develop your message: Learn how to create a focused, engaging message.
68. Write a press release: Even if you don’t work in PR or marketing, being able to write a press release is a valuable, desirable skill personally and professionally.
69. Follow up: Make sure you follow up on promises and after meeting new people.
70. Identify an audience: Learn how to rework your message depending on who you’re speaking to.

Speaking and Communication

From better storytelling to learning a new language or becoming an effective public speaker, these communication skills will make you more influential and confident.

71. Learn a foreign language: Speaking at least two languages greatly increases your desirability as a job candidate.
72. Storytelling: For presentations and networking, it helps if you’re a good storyteller.
73. Keep it simple: Don’t babble; instead, learn to speak clearly and simply.
74. How to make transitions: Making smooth transitions in your talks and presentations will strengthen your speech overall.
75. Deliver bad news: You should learn how to be diplomatic and break bad news considerately.
76. Consider things from different points of view: Relate to your audience and act like a fair leader by considering various points of view.
77. Give a compliment: If you’re uncomfortable giving compliments, you’d better learn how to get over it.
78. Negotiate: Negotiate salary, job offers, payment, and more.
79. Conflict management: Learn how to be more diplomatic and solve problems in the workplace.
80. Speak to executives: Don’t be afraid to talk to the boss, just make sure you do it the right way.

Finance

Save money and learn smarter budgeting tips here.

81. Open a Roth IRA: Use a little of the money you have saved to start a Roth IRA for the future.
82. Pay taxes as a freelancer: If you’re freelancing between full-time jobs, you’ll need to learn how to do your own taxes.
83. Turn eBay into a money-maker: While you’re out of work, learn how to use eBay to make extra cash.
84. Haggle: Get better deals on food, entertainment, clothes and more when you learn to haggle.
85. Lower your cell phone bill: Learn how to lower your cell phone bill when you’re tightening your budget.
86. Get a tax extension: If you just can’t pay your taxes this year because you’re unemployed, learn how to get an extension.
87. Consolidate debt: This skill may help you with a finance problem at work and alleviate some of the burden of high interest rates.
88. Make a budget: This practical skill will save you money and help you trim expenses at work.
89. Find a bargain: Learn when to go generic and hunt for bargains.
90. Save: Practice restraint by setting up savings accounts and spending less.

Weird Skills

You never know when you’ll need to win a fist fight or have to know your tolerance for alcohol, so practice now.

91. Win a fist fight: Man up and learn how to win a fist fight or street fight.
92. Be more photogenic: Look more attractive and confident in photographs.
93. Know your tolerance: Before getting wasted at networking events or office parties, know how much booze you can handle.
94. Be a respectful house guest: Review basic etiquette and send a thank-you note the next day.
95. Know when someone is lying: Be able to tell when someone else is lying to protect yourself.

Miscellaneous

From tying a tie to taking better notes, here are more skills you should learn while you’re unemployed.

96. Stay on top of industry news: Make reading industry reports and niche news blogs a habit for when you’re unemployed and when you get a job.
97. Get comfortable with international travel: Even if you can’t afford a plane ticket, read world news, learn a language and keep up with other cultures to broaden your horizons and show potential employers that you’re open to traveling for them.
98. Tie a tie: Make sure you always look presentable by tying your tie correctly.
99. Keep your brain active: Keep learning so that you’re in shape to tackle new challenges when you do find a job.
100. Take better notes: Learn to take notes during interviews and meetings.

There you have it!

Until next time...

Good Luck and Good Job Hunting!!!!

• Email This
• Print
• Trackbacks
• Share Link

I came across a recent post on Adage.com entitled “Pharma Drops Search Advertising After FDA Warning” that revealed that paid search ads by pharmaceutical companies dropped a 84% between March 26 of this year and the end of June. As you may recall, March 26 was when 14 companies received warning letters from the US Food and Drug Administration (FDA) indicating that they had violated marketing guidelines for search ad advertising. The letters stated that sponsored-link advertisements for specific drugs were misleading due to the exclusion of risk information associated with the use of the drug -- even though the regulatory agency's guidelines are for print and broadcast, not online or social media. Pharma companies that believed they were in compliance with the unwritten "one-click rule"— taking the consumer from the ad to a site that offered fair balance and the risk information by clicking on the ad. What? Did I read that correctly; the words “unwritten and FDA” in the same sentence? This is very surprising since anybody who has worked with the agency is well aware of the “if it isn’t written it didn’t happen” principle. But I digress....

The post went on to say that pharmaceutical companies are “fearful of running afoul” of the agency again. Say what? The words “pharma and fearful” used in the same sentence? The point that I am trying to make is that pharma chose to keep things vague about web-based advertising to see how far they can push the envelope with FDA instead of taking the proverbial “bull by the horns” and directly asking FDA for guidance on web 2.0 technologies and their uses. Wouldn’t it be in everyone’s best interest if companies took a more active role to help craft new rules on the use of new media technologies rather then rely on and wait for FDA to do it for them? While the old “cat and mouse” game worked for old media, it is no longer tenable when it comes to Web 2.0 and related technologies.

The FDA is holding public hearings next month to begin the process of establishing internet advertising guidelines and the use of social media in the life science industry. This offers drug and devices companies an opportunity to show FDA that they no longer want to be part of the problem but part of the solution.  I have always subscribed to the notion that “you don’t get if you don’t ask!”

Until next time...

Good Luck and Good Surfing (on the Internet that is)

blog comments powered by Disqus

• Email This
• Print
• Trackbacks
• Share Link

For the first time in history, more people are searching the Internet for health information than asking doctors. Web 2.0 and social media tools are allowing people to discover new ways to connect, learn and engage one other in search of healthcare and drug information.

e-Patient Connections 2009 which will be held in Philadelphia, PA on  October 26 and 27 will feature a number of leading authorities on social media and digital health  Some of the featured speakers include Wired Magazine’s Thomas Goetz, Jay
Bernhardt of the CDC, and Lee Aase of the Mayo Clinic. The conference also offers case studies, 1:1 coaching sessions with industry experts and the latest products from digital health companies.

BioJobBlog readers can use the discount code kru500 to save $500 off the current price.

See you there!

• Email This
• Print
• Trackbacks
• Share Link

There was another article in today’s New York Times lamenting the marketing practices utilized by drug companies to inform physicians about their products. While these practices may be troubling to legislators and the American public, everybody who works in the life sciences industry including regulatory agencies like the US Food and Drug Administration (FDA) understands the “rules of the game” and how it is played. However,

over the past three years, there has been a full frontal assault on direct-to-consumer advertising and marketing and sales practices used by drug makers to hawk their products to physicians and the American public. This has largely been an over reaction to the lack of regulatory oversight of drug manufacturers during the Bush administration. The new regulations have severely limited what sales representatives can offer physicians e.g. gifts and free lunches and dinners, for more face time to sell their products. Consequently, the only means left available to drug makers to reach large numbers of physicians is marketing through medical education.

This is how it works. Companies annually budget monies to pay highly recognized physicians aka key opinion leaders (KOLs) to give lectures to physicians that might influence their prescribing habits. These lectures often take the form of informational seminars that focus on treatment options for certain therapeutic indications which often times subliminally highlight the advantages of the sponsor’s product over its competitors. Not surprisingly, the effectiveness and success of these programs is usually directly proportional to the sums of money invested in them. For example, in 2004, Forrest Laboratories (the subject of the NY Times article) planned on spending “$34.7 million to pay 2000 physicians to deliver 15,000 marketing lectures about Lexapro (an antidepressant) to their peers in one year.” The investment appears to have paid off; sales Lexapro reached $2.3 billion in 2008 even though a lower cost generic version of the drug is available. And, while the Forrest investment in medical education may appear to be a large one, it pales in comparison to the sums invested in medical education programs by much larger companies like Pfizer, Merck and others.

While certain members of Congress may be “shocked and outraged,” these practices are sanctioned by FDA. And, as long as drug makers are compliant and adhere to the rules they shouldn’t be faulted or penalized for their efforts. The point that I am trying to make is that drug makers, like all other for-profit entities, must maximize sales to generate sufficient profits remain in business. Therefore, it should come as no surprise to legislators or the American public for that matter, that drug makers use all legally available means to maximize the sale of their products. If Congress doesn’t like what drug makers are doing, then they ought to stop complaining and legislate changes to the rules. Put simply, it’s time for Congress to “put up or shut up.”

Until next time...

Good Luck and Good Job Hunting!!!!

• Email This
• Print
• Trackbacks
• Share Link

Lisa Roner, blogger and editor for EyeforPharma, recommends a podcast on social media that was created by Dr. Andree Bates, CEO at Eularis, a company that applies analytics to determine the sales impact of specific marketing programs.

Dr. Bates says it is an important area for pharmas to become engaged in social media.  In the podcast, she offers some ideas about how pharma marketers might apply these channels effectively. Also, she offers some tips and hints for intrepid pharma employees who are interested in getting started.

To listen to the podcast click here.

Until next time...

Good Luck and Good Networking!!!!!!!!

• Email This
• Print
• Trackbacks
• Share Link

I suspect that a majority of BioJobBlog readers have at one time or another been prescribed a drug to treat a particular medical condition or ailment. Like most of you, I assumed that my prescription information and history was private and that only healthcare professionals were privy to it. However, after reading an article in this Sunday’s NY Times, I learned how wrong I was! Much to my dismay,  I learned that prescription information including the name and dosage of a drug, the name and address of the physician who prescribed as well as a patient’s address and social security number is a commodity that is regularly bought and sold usually with a patients’ knowledge or permission. And apparently, this practice is perfectly legal as long as patient’s names are removed or encrypted before the information is sold, typically to drug manufacturers.

Unfortunately, privacy experts and information technology specialists contend that it isn’t difficult to match names, addresses, and social security numbers to reconstruct information that had supposedly been rendered anonymous. To make matters worse, until very recently, federal patient privacy and data security rules were loosely enforced and frequently abused by medical marketers, advertisers, drug manufacturers and retail pharmacies. Finally, re-identifying a patient’s prescription drug information and history provides drug makers with a powerful tool to target and market drugs to specific patient populations.

Tracking prescriptions and mining prescription data is not new—it has been big business for many decades. The major players in the drug mining business are companies like IMS Health, Verispan and CVS Caremark. Also, large discount pharmacy retailers like Walgreens and Target engage in this practice and they all sell their prescription information data to interested parties. Prescription drug data-mining companies say that their services are valuable and warranted because gathering and analyzing information from tens of thousands of patients helps drug manufacturers to identify trends and potential safety and tolerability issues with prescription drugs. Nevertheless, despite assertions that prescription drug data are anonymous when it is sold, class action and private lawsuits alleging this not to be the case have been filed against some of the major players including Walgreens, IMS Health and CVS Caremark. While this is troubling, loopholes in the current prescription drug data mining regulations allow pharmacy companies like Walgreens and others to accept money from drug manufacturers to mail advice and reminders to customers to take their medications without first obtaining their permission. The loopholes also allow drug makers to send customers’ promotional information and materials about drugs other than the ones that they are already taking.

Under the Obama Administration’s $19 billion healthcare stimulus package, selling prescription drug data to drug makers will still be allowed (only if patient’s names are removed). Also, subsidized marketing by drug makers will be allowed to continue but companies will no longer be able to promote drugs other than those the customer already buys. While the new legislation allows data mining and the sale of prescription drug information to continue, its primary goal is to tighten and insure patient privacy so that personal prescription drug history and information can no longer be used to exploit the buying habits and behaviors of individual American consumers.

Until next time...

Good Luck and Good Job Hunting!!!!

• Email This
• Print
• Comments (1)
• Trackbacks
• Share Link

It’s no secret that major pharmaceutical companies are no longer investing in internal drug discovery initiatives as much as they have in the past. However, I was unaware how drastic the decline in R&D spending was until I read an article entitled “Significant Change Predicted for Bioindustry” by Benjamin J. Conway in the July issue of Genetic Engineering & Biotechnology News. 

Mr. Conway notes that in 1989 more than 50% of the pharmaceutical industry’s budget was spent on preclinical drug discovery and development. During the 1990s, the percentage slowly declined and was approximately 44% by 1999. He asserts that beginning in 2000, “the drop became precipitous” as pharmaceutical companies spent increasing amounts of their R&D budgets on downstream activities including expanded clinical trials. By 2006, big pharma was spending about 25% of its budget on R&D. Strikingly, Mr. Conway contends that “when measured in terms of constant absolute dollars, spending on pre-clinical R&D activities actually declined 0.4% annually over the period, despite annual increases of nearly 7% in total R&D spending.” 

Not surprisingly, the almost decade-long decrease in pharmaceutical R&D spending is best reflected in the lack of new drug approvals over the past five years or so. According to Mr. Conway, throughout the 1990s more than 50% of all new drug approvals originated at big pharma companies. By 2001, these companies were responsible for approximately 60% of new drug approvals. However, since then, pharma’s new drug approvals have plunged to 25% to 30% of annual totals. Some analysts suggest that the figure has been as low as 15%. The decline in new drug approvals almost parallels the decrease in R&D spending at most major pharmaceutical companies. Many industry analysts and thought leaders contend that big pharma companies have gotten too big and unwieldy and can no longer innovate. The unprecedented drops in pharma’s new drug approval rates tend to support that assertion. Mr. Conway points out that the so-called “innovation gap” has been filled by biopharmaceutical companies that “today account for 75% or more of new therapeutics developed each year.”

These changing market dynamics suggests that big pharma must reconfigure the business model that it has clung to for the past 50 years to remain competitive. Not surprisingly, almost all of the major pharmaceutical companies have begun to do just that! For example, over the past three years more than 60,000 R&D scientists have lost their jobs with little likelihood that the vacated jobs will ever be resurrected. Further, big pharmaceutical companies have increasingly begun to outsource many R&D activities to Asia, Eastern Europe and elsewhere. Finally, most big pharma companies have publicly demonstrated—through mergers and acquisitions—that biotechnology products as well as small molecules are in their future.

While big pharma may be retrenching and evolving, don’t expect the pharmaceutical industry on internal drug discovery initiatives —or small molecules for that matter— to disappear any time soon. The industry is going through a transitional period and the companies of the future will look only slightly different than they do today. These companies will still be large and well capitalized, but likely more diversified in their product portfolios (which will surely contain biotechnology drugs). Also, they will continue to excel in new product development, marketing and distribution. However, unlike the past, much less emphasis will be placed on internal R&D programs to discover new molecular entities. This means that pharmaceutical R&D operations will remain lean and companies will increasingly rely on M &A and licensing deals (with smaller specialty pharma and biotechnology companies) to keep their pipelines full.

Until next time...

Good Luck and Good Job Hunting!!!!!!!!!!

• Email This
• Print
• Trackbacks
• Share Link

Johnson & Johnson (JNJ) is trying to regain sole marketing rights to Remicade, its lucrative anti-TNF treatment for arthritis and psoriasis, because Schering Plough (SGP)—which has most of the marketing rights to the drug outside of the US—is being acquired by Merck. JNJ is seeking arbitration to determine whether or not Centocor, its subsidiary that manufactures Remicade and Simponi, can terminate a marketing agreement for the two drugs—based on terms stipulated in the original contract —if there is a “change of control” at SGP.

As you may recall, Merck was acutely aware of the terms of marketing agreement before it decided to purchase SGP and cleverly engineered the acquisition as a reverse merger— to prevent triggering provisions that could return Schering’s marketing rights for Remicade and Simponi to JNJ if their were leadership changes or a change of control at SGP. JNJ’s announcement contesting wasn’t unexpected after the Merck-Schering Plough deal was announced early last winter—sales of Remicade outside of the US topped $2.0 billion in last year. Simponi, Remicade’s highly touted successor (which recently received FDA approval), is also expected to reach blockbuster status after it reaches the market. 

The Merck-Schering deal left JNJ with few alternative or choices. The company could have counter offered to purchase SGP in its entirety or simply, as it did, invoke terms of the original agreement that would terminate SGP’s marketing rights if there was a “change of control” at the company. JNJ rightfully believes that a change of control will occur when Merck acquires SGP. According to a JNJ spokesperson “As its public statements make clear Merck is acquiring Schering Plough. The acquisition constitutes a change of control and trigger’s Centocor’s right to terminate.” It will be interesting to see how an arbitrator rules in the case.

While the loss of Remicade and Simponi isn’t likely to jeopardize the Merck-Schering Plough deal (according to Merck executives), it may affect the financial terms and overall benefit or upside of the acquisition. The expected completion of the deal is scheduled for the fourth quarter of this year.

Until next time...

Good Luck and Good Job Hunting!!!!

• Email This
• Print
• Trackbacks
• Share Link

Twitter, the microblogging platform, is the current rage in social media. According to @Shwen, who writes the Med 2.0 Blog, it grew by 752% in 2008. Shwen is a social media enthusiast who is trying to convince the life sciences industry that Twitter and other social networks can be leveraged to improve drug development and deliver healthcare.

According to a recent post on Med. 2.0, there are currently three pharmaceutical companies that are actively using Twitter: Novartis (@novartis), Boehringer Ingelheim (@Boehringer) and Astra Zeneca (AstraZenecaUS). Also, it appears that Johnson and Johnson (@JNJcomm) launched an account last week. Tweets from @novartis and @Boehringer occur fairly regularly whereas AstraZenecaUS tweets are rare. Unlike YouTube, where pharmaceutical sponsors who create channels can regulate and control content, it is much more difficult to manage Twitter because tweets are in real time, uncensored (for the most part) and can be globally disseminated within seconds.

Despite these issues, Med 2.0’s Shwen muses “I can only imagine that more pharma companies are going to be jumping on board the Twitter-train sooner rather than later. How they use it to engage, on the other hand, is going to vary greatly from company to company. At the very least, I see companies setting up accounts as “listening posts”, but others may choose to engage, like @boehringer does in an informal manner. Whatever the case, Twitter is fast becoming the new dominant space for listening and/or engaging the life sciences community.”

Like Shwen, I believe that it a matter of time before pharma and biotech realize that they must embrace social media (in all of its various forms) to remain competitive in today’s increasingly interconnected marketplace.

For those of you who may be interested, you can follow BioJobBlog (@Biojobblog) and Biocrowd (@Biocrowd) on Twitter too!

Until next time…

Good Luck and Good Twittering

• Email This
• Print
• Trackbacks (1)
• Share Link

News Day reported today that Wegmans Food Markets, a grocer with 72 locations in New York, Pennsylvania, New Jersey, Virginia and Maryland is giving away “free generic antibiotics” for customers (with a prescription). Wegmans joins a growing list of supermarkets pharmacies including Giant Food and Publix that are giving free generic antibiotics to its customers.

I first learned about the “free generic antibiotic give away offers” several weeks ago after reading a post on the Wall Street Journal (WSJ) Health Blog. I took the WSJ health blog to task for posting the story without editorial comment on the potentially dangerous practice of “hawking free antibiotics” to drive business at regional and nationwide grocery store pharmacies. Luckily, in today’s WSJ Health Blog post about the Wegmans program, the author (Sarah Rubenstein) did suggest that the practice may lead to unnecessary promotional  use of antibiotics.

As you all should know by now, we are in the midst of bacterial antibiotic-resistance epidemic. People are beginning to regularly die from bacterial infections that were easily treatable a decade ago. Ironically, we are slowly approaching the morbidity and mortality rates for bacterial infections that previously existed in the pre-penicillin era. Moreover, there are no new, orally bioavailable, broad spectrum antibiotics on the horizon. A lack of new antibiotics coupled with rapidly emerging resistance to extant ones is wreaking havoc on the healthcare system in both community and hospital settings.

The “free generic antibiotics” advertising and marketing programs concocted by Giant, Publix and Wegman’s are egregious examples of how a lack of or unwillingness to understand science poses a serious public health threat to all Americans. I have no doubt that the marketers who devised the give away programs have nary a clue about the relationship between antibiotic use and the emergence of antibiotic resistance strains of bacteria. Further, while physicians may be aware of increasing rates of antibiotic resistance, many are reluctant to not prescribe antibiotics to patients who request them. After all, these physicians are running a business and if they don’t write the script, the patient will take his/her business elsewhere. The potential public health implication of these free antibiotic programs begs the question: Why not give away generic ace inhibitors, generic statins or other generic medications whose profits margins are also negligible but don’t carry any public health risks?

Put simply, the promise of free generic antibiotics is a marketing strategy that is in my opinion, reckless, dangerous and may have serious public health implications in the future. Make no mistake about it, I am a capitalist but not when profits are placed before human lives.

Hat tip to the WSJ Health Blog

Until next time…

Good Luck and Good Job Hunting (try antibiotic drug discovery—we need new ones)

• Email This
• Print
• Comments (1)
• Trackbacks
• Share Link

An article in today’s New York Times reports that several FDA scientists have accused the agency of granting market approval to several unsafe medical devices. According to published reports, “the House Committee on Energy and Commerce will investigate the accusations, first aired when eight agency scientists wrote a private letter in May to FDA commissioner Andrew von Eschenbach.”

Unfortunately, the allegations made by the eight scientists against the agency are nothing new. Frequently, agency managers (and sometimes political appointees) lean toward approving drugs or devices when the data pertaining to efficacy and safety are equivocal.

My sources at FDA suggest that this is what happened with approval of Merck’s ill-fated pain medication Vioxx.

Recently, there has been a spate of safety claims made against medical devices manufacturers. This is not surprising because the regulatory hurdles for marketing approval of devices are much lower for devices as compared with drugs and the medical devices and diagnostics business is the fastest growing sector in the life sciences. For an overview of the medical devices and diagnostics industry please read my recent article published in Science Careers.

Hopefully, new leadership at the agency will turn things around!!!!!!!

Until next time…

Good Luck and Good Job Hunting!!!!!!!!

.

• Email This
• Print
• Trackbacks
• Share Link

According to a post on the Wall Street Journal Health blog, Wyeth announced today that it is laying off about 1,200 marketing and sales representatives who helped support Protonix, its blockbuster heartburn and acid reflux medication. The job cuts are part of a previously announced “asset reallocation plan” that is designed to reduce the size of the company’s workforce by about 5% this year, and by 10% over the next three years.

The company employees about 50,000 people worldwide with roughly half of them in the U.S.  Like some of its competitors, Wyeth is facing stiff generic competition for several products that are slated to lose patent protection over the next couple of years and recently has had trouble getting many of its new drugs approved by the US Food and Drug Administration.

Until next time….

Good Luck and Good Job Hunting!!!!!!!!!!!

• Email This
• Print
• Comments (1)
• Trackbacks
• Share Link

Still reeling from lawsuits filed last week by ex-sales reps’ alleging improper marking of Enbrel to treat patients with psoriasis, Amgen was subpoenaed on Monday by New Jersey's attorney general regarding allegations that the company promoted Enbrel for unapproved uses.

In the subpoena served Monday, Attorney General Anne Milgram is seeking "a comprehensive array of documents and information" concerning the marketing and sale of Enbrel from July 2002 to the present.

The subpoena calls for Amgen to deliver the required materials by Feb. 4.

Although doctors are free to prescribe medicines as they see fit, drug companies are only allowed to promote their products for uses that have been approved by the U.S. Food and Drug Administration and appear on product labels.

Until next time…

Good Luck and Good Job Hunting!!!!!!!!

• Email This
• Print
• Trackbacks
• Share Link